iBio, Inc. (IBIO) has a negative trailing P/E of -8.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -11.29%.
Criteria proven by this page:
Overall SharesGrow Score: 41/100 with 0/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -6.0 | -0.18 | 5.87 | 61.50 | - |
| 2017 | -2.4 | -0.07 | 3.90 | 88.21 | - |
| 2018 | -0.6 | 0.16 | 0.59 | 21.55 | - |
| 2019 | -0.8 | 0.02 | 5.38 | 6.57 | - |
| 2020 | -8.5 | 0.24 | 2.46 | 85.11 | - |
| 2021 | -12.7 | 0.16 | 2.72 | 124.58 | - |
| 2022 | 0.0 | 0.00 | 0.04 | 1.20 | - |
| 2023 | -0.1 | 0.00 | 0.49 | 0.00 | - |
| 2024 | -0.3 | 0.00 | 0.36 | 34.22 | - |
| 2025 | -0.4 | 0.01 | 0.54 | 20.03 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-600.00 | $948K | $-9.76M | -1030% |
| 2017 | $-20.38 | $394K | $-14.53M | -3688.3% |
| 2018 | $-18.94 | $444K | $-16.11M | -3627.3% |
| 2019 | $-35.25 | $2.02M | $-17.59M | -871.8% |
| 2020 | $-40.26 | $1.64M | $-16.44M | -1003.6% |
| 2021 | $-60.00 | $2.37M | $-23.21M | -978.8% |
| 2022 | $-58.49 | $1.88M | $-51.01M | -2707.3% |
| 2023 | $-23.94 | $0.00 | $-29.31M | - |
| 2024 | $-6.50 | $225K | $-24.91M | -11069.8% |
| 2025 | $-1.75 | $400K | $-18.38M | -4594.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.31 | $-0.34 – $-0.27 | $180K | $78.26K – $391.3K | 3 |
| 2027 | $-0.29 | $-0.38 – $-0.18 | $120K | $92.31K – $197.8K | 3 |
| 2028 | $-0.35 | $-0.65 – $-0.25 | $250K | $192.31K – $412.09K | 1 |
| 2029 | $-0.47 | $-0.86 – $-0.33 | $500K | $384.62K – $824.18K | 1 |
| 2030 | $-0.46 | $-0.85 – $-0.32 | $500K | $384.62K – $824.18K | 1 |
